Synopsis Present guidelines recommend rituximab or cyclophosphamide for the treatment of organ-threatening disease in anti-neutrophil cytoplasm antibody (ANCA)-associated vasculitis (AAV). This study aimed to confirm high rates of clinical response and prolonged B-cell depletion associated with low relapse rates and improved patient and renal survival during long-term follow-up. This week’s “ MED FACT ” discusses a clinical trial from Nephrology Dialysis Transplantation, “ Long-term follow-up of a combined rituximab and cyclophosphamide regimen in renal anti-neutrophil cytoplasm antibody-associated vasculitis ”.
Authors : McAdoo S P et.al. Key Takeaways: Rituximab and cyclophosphamide combination regimen is potentially superior to current standards of care in AAV. Objective: This study aimed to confirm high rates of clinical response and prolonged B-cell depletion associated with low…
